Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.36 |
| ▸ | GUCY1B2 | O75343 | 9/20 | 0.34 |
| ▸ | GUCY1A2 | P33402 | 9/20 | 0.34 |
| ▸ | GUCY1A1 | Q02108 | 9/20 | 0.34 |
| ▸ | GUCY1B1 | Q02153 | 9/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | GPR6 | P46095 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711750 | 0.98 | KDM1A (0.39) | KDM1ARCOR1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL6710365 | 0.96 | KDM1A (0.39) | KDM1ARCOR1CHRM3MAOAGPR6 | |
| SCHEMBL6713385 | 0.90 | PTGER1 (0.38) | KDM1ARCOR1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL6713351 | 0.90 | PTGER1 (0.38) | KDM1ARCOR1CHRM3GRM5 | |
| SCHEMBL6708943 | 0.90 | MAPT (0.36) | KDM1ATSHRMAOA | |
| SCHEMBL6709157 | 0.88 | GPR6 (0.38) | KDM1AMAOAGPR6 | |
| SCHEMBL6713780 | 0.88 | KDM1A (0.36) | KDM1ARCOR1GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL6710481 | 0.88 | PTGER1 (0.37) | KDM1ARCOR1CHRM3 | |
| SCHEMBL6708936 | 0.88 | KDM1A (0.34) | KDM1AMAOAGPR6 | |
| SCHEMBL6710432 | 0.86 | LMNA (0.35) | KDM1ARCOR1CHRM3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | KDM1A 620/4885RCOR1 3366/4885GUCY1B2 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.